Sign In
Buy ONCY
$0.92
-0.0428 (-4.46%)
At Close: Jun 22, 2026
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
09:00am, Tuesday, 16'th Jun 2026
Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional pa
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, syste
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial d
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
09:00am, Friday, 22'nd May 2026
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
12:42pm, Monday, 04'th May 2026
Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherapy, pelareorep, in treating metastatic colorectal ca
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
09:00am, Monday, 04'th May 2026
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L R
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
08:10am, Monday, 27'th Apr 2026
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
04:27am, Saturday, 25'th Apr 2026
Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially imp
Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY)
02:31am, Friday, 24'th Apr 2026
Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) and Erasca (NASDAQ: ERAS - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on t
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
09:00am, Monday, 06'th Apr 2026
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investi
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of “Moderate Buy” from Analysts
02:20am, Monday, 06'th Apr 2026
Oncolytics Biotech Inc. (NASDAQ: ONCY - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are covering the stock, Marketbeat reports. One research ana
Oncolytics Biotech® Completes Domicile Change to the United States
09:00am, Wednesday, 01'st Apr 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today anno
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
11:00am, Thursday, 19'th Mar 2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the large
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
09:00am, Thursday, 19'th Mar 2026
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RA
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
09:00am, Monday, 02'nd Mar 2026
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRA
